BCL6 and diffuse large B-cell lymphoma: At the molecular level, HBsAgpos DLBCL had, compared to HBsAgneg DLBCL, an increased total mutation load especially involving BCL6 and the FOXO signaling pathway; this was believed to reflect an infection-driven hyperactive status of B-cells leading to enhanced mutational activity [3].